Healthcare Provider Information | AJOVY™ (fremanezumab-vfrm) injection

You are now leaving this web site

This Web site may contain links or references to other Web sites maintained by third parties over whom Teva, Inc. ("Teva") has no control. Links are provided as a convenient resource to our visitors. We carefully choose Web sites which we believe are useful based on our high standards. However, Web sites can change. Teva cannot guarantee the standards of every Web site link or be responsible for the content of non-Teva Web sites. Inclusion of any third-party link does not imply an endorsement or recommendation by Teva.

Similarly, this Web site may be accessed from third-party links over which Teva has no control. Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such Web sites and shall have no liability for any damages or injuries of any kind arising from such content or information.

Help your patients say yes to more moments.¹

AJOVY is the only anti-CGRP treatment for the prevention of migraine with quarterly (225 mg x 3) and monthly (225 mg) dosing options.¹

AJOVY helped significantly reduce monthly migraine days vs placebo¹
See the clinical trial data for AJOVY

Flexibility to help you meet your patients' needs¹
dosing options for ajovy

Safety profile in clinical trials for AJOVY¹
safety profile for ajovy

Support for you and your patients

Patients pay as little as #{offerValue}# for AJOVY*

Your commercially insured patients can use this offer and save on AJOVY.
*Eligibility and restrictions apply.

Savings Offer

Insurance coverage support

Quickly access and submit a health plan–specific prior authorization form for AJOVY.

Get Started

Administering AJOVY

AJOVY may be administered by healthcare professionals in the office, or at home by patients and/or caregivers.

administering AJOVY

CGRP: calcitonin gene-related peptide.